Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARCT Arcturus Therapeutics	$11.82 -1.7%	$11.31	$8.04 ▼ $45.00	$320.57M	2.36	447,878 shs	322,037 shs
NAMS NewAmsterdam Pharma	$17.31 +1.8%	$18.19	$14.06 ▼ $27.29	$1.90B	0.01	641,002 shs	539,457 shs
PNT POINT Biopharma Global		$12.98	$6.57 ▼ $14.35	$1.33B	N/A	1.44 million shs	3.29 million shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARCT Arcturus Therapeutics	-1.75%	-2.72%	-7.80%	-26.30%	-69.23%
NAMS NewAmsterdam Pharma	+1.76%	-6.48%	-2.92%	-17.22%	-10.82%
PNT POINT Biopharma Global	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARCT Arcturus Therapeutics	2.8303 of 5 stars	4.6	0.0	0.0	0.0	2.6	2.5	0.6
NAMS NewAmsterdam Pharma	2.4602 of 5 stars	3.5	1.0	0.0	0.0	2.2	5.0	0.0
PNT POINT Biopharma Global	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARCT Arcturus Therapeutics	3.11	Buy	$53.50	352.62% Upside
NAMS NewAmsterdam Pharma	3.00	Buy	$43.00	148.41% Upside
PNT POINT Biopharma Global	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest ARCT, PNT, and NAMS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/28/2025	ARCT Arcturus Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$32.00
5/14/2025	ARCT Arcturus Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$50.00 ➝ $45.00
5/13/2025	ARCT Arcturus Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/13/2025	ARCT Arcturus Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$68.00 ➝ $66.00
5/8/2025	NAMS NewAmsterdam Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$42.00 ➝ $40.00
4/10/2025	ARCT Arcturus Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00
4/8/2025	NAMS NewAmsterdam Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$42.00 ➝ $42.00
3/10/2025	ARCT Arcturus Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$48.00
3/10/2025	ARCT Arcturus Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$74.00 ➝ $68.00
3/7/2025	ARCT Arcturus Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$63.00 ➝ $60.00
3/7/2025	ARCT Arcturus Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight

(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARCT Arcturus Therapeutics	$131.27M	2.44	N/A	N/A	$10.42 per share	1.13
NAMS NewAmsterdam Pharma	$47.14M	40.33	N/A	N/A	$3.50 per share	4.95
PNT POINT Biopharma Global	$226.58M	0.00	N/A	13.31	$4.68 per share	0.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARCT Arcturus Therapeutics	-$29.73M	-$2.53	N/A	N/A	N/A	-36.39%	-22.39%	-14.81%	8/4/2025 (Estimated)
NAMS NewAmsterdam Pharma	-$176.94M	-$1.88	N/A	N/A	N/A	N/A	N/A	N/A	8/6/2025 (Estimated)
PNT POINT Biopharma Global	$98.29M	$0.90	13.89	N/A	N/A	39.62%	21.10%	18.28%	N/A

Latest ARCT, PNT, and NAMS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	ARCT Arcturus Therapeutics	-$1.58	-$0.52	+$1.06	-$0.52	$25.64 million	$29.38 million
5/8/2025	Q1 2025	NAMS NewAmsterdam Pharma	-$0.45	-$0.49	-$0.04	-$0.34	$1.46 million	$2.98 million
3/6/2025	Q4 2024	ARCT Arcturus Therapeutics	-$0.33	-$1.11	-$0.78	-$1.11	$44.64 million	$22.77 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARCT Arcturus Therapeutics	$0.71	6.05%	N/A	N/A	N/A
NAMS NewAmsterdam Pharma	N/A	N/A	N/A	N/A	N/A
PNT POINT Biopharma Global	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARCT Arcturus Therapeutics	N/A	4.76	4.76
NAMS NewAmsterdam Pharma	N/A	10.61	10.61
PNT POINT Biopharma Global	0.01	9.14	9.14

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARCT Arcturus Therapeutics	94.54%
NAMS NewAmsterdam Pharma	89.89%
PNT POINT Biopharma Global	59.53%

Insider Ownership

Company	Insider Ownership
ARCT Arcturus Therapeutics	16.60%
NAMS NewAmsterdam Pharma	20.84%
PNT POINT Biopharma Global	16.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARCT Arcturus Therapeutics	180	27.12 million	22.94 million	Optionable
NAMS NewAmsterdam Pharma	4	109.82 million	74.37 million	Optionable
PNT POINT Biopharma Global	129	106.57 million	89.52 million	Optionable

ARCT, PNT, and NAMS Headlines

Recent News About These Companies

Lantheus on POINT in radio-oncology with $2bn licensing deal

September 14, 2024 | pharmaphorum.com

Sustainability: A Key Differentiator as Biopharma Faces Momentum Challenges, According to Global Survey by Cytiva

August 21, 2024 | genengnews.com

Prota Therapeutics Strengthens Board with Appointment of Global Biotech Expert Patrick Machado

July 24, 2024 | markets.businessinsider.com

How to deliver an effective global strategic brand plan

July 19, 2024 | pharmaphorum.com

What's Going On With GT Biopharma Stock?

May 20, 2024 | msn.com

How Merck is stepping up for patients

May 19, 2024 | pharmaphorum.com

Point Digital Finance prints second HEI RMBS

May 9, 2024 | globalcapital.com

Investing in biopharma innovation: Can you stay one step ahead?

April 8, 2024 | bloomberg.com

Global Point of Care Molecular Diagnostics Industry Aims for a Striking US$11.1 Billion Market by 2033, Fueled by a 9.7% CAGR | FMI

March 14, 2024 | fmiblog.com

Reshaping The Global Neopentyl Glycol Dicaprate Market With Latest Trends And Market Opportunities

February 21, 2024 | opprairie.com

Comprehensive Overview of the Pharmaceutical Grade Ambrisentan Market along with Emerging Trends, Challenges, and Potential Threats

February 13, 2024 | opprairie.com

Domain Therapeutics Strengthens Leadership Team to Spearhead Global Development and North American Expansion as the Leading GPCR Immuno-Oncology Company

January 8, 2024 | businesswire.com

Lilly Completes Acquisition of POINT Biopharma

December 27, 2023 | finance.yahoo.com

POINT Biopharma Global Rating Adjustment: Hold Recommendation Following Shareholder Dynamics and Acquisition Prospects

December 22, 2023 | markets.businessinsider.com

Brookline Capital Downgrades POINT Biopharma Global (PNT)

December 22, 2023 | msn.com

POINT Biopharma Global Stock (NASDAQ:PNT), Guidance and Forecast

December 22, 2023 | benzinga.com

Lilly extends tender offer for POINT Biopharma to Dec. 22

December 18, 2023 | msn.com

Why POINT Biopharma Global Is At Least A Hold On Disappointing Readout

December 18, 2023 | seekingalpha.com

Lantheus Holdings And POINT Biopharma Announced Lu-PNT2002 Phase 3 SPLASH Study Results

December 18, 2023 | markets.businessinsider.com

POINT Biopharma Global Inc. (PNT) Upgraded to Buy: Here's What You Should Know

December 8, 2023 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARCT, PNT, and NAMS Company Descriptions

Arcturus Therapeutics NASDAQ:ARCT

$11.82 -0.21 (-1.75%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$11.84 +0.02 (+0.16%)

As of 05/28/2025 07:44 PM Eastern

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

NewAmsterdam Pharma NASDAQ:NAMS

$17.31 +0.30 (+1.76%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$17.31 0.00 (-0.01%)

As of 05/28/2025 06:42 PM Eastern

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

POINT Biopharma Global NASDAQ:PNT

POINT Biopharma Global Inc., a radiopharmaceutical company, develops and commercializes radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of prostate cancer, which is under preclinical studies; and PNT-2004, a fibroblast activation protein-alpha inhibitor targeting program being developed for use in various tumor types that is under preclinical studies. In addition, it has product candidates being developed on CanSEEK technology sub-licensed from both Bach Biosciences LLC and Avacta Life Sciences Limited. POINT Biopharma Global Inc. was founded in 2019 and is headquartered in Indianapolis, Indiana.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time